218 related articles for article (PubMed ID: 34616699)
1. Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.
Shenkoya B; Atoyebi S; Eniayewu I; Akinloye A; Olagunju A
Front Pediatr; 2021; 9():734122. PubMed ID: 34616699
[TBL] [Abstract][Full Text] [Related]
2. Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice.
Dyavar SR; Gautam N; Podany AT; Winchester LC; Weinhold JA; Mykris TM; Campbell KM; Alnouti Y; Fletcher CV
J Antimicrob Chemother; 2019 Oct; 74(10):2974-2978. PubMed ID: 31335938
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
Tran AH; Best BM; Stek A; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; George K; Cressey TR; Chakhtoura N; Smith E; Shapiro DE; Mirochnick M;
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):289-96. PubMed ID: 26918544
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Modeling of the Drug-Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?
Dallmann A; van den Anker J; Ahmadzia HK; Rakhmanina N
J Clin Pharmacol; 2023 Jun; 63 Suppl 1():S81-S95. PubMed ID: 37317489
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
Bollen P; Freriksen J; Konopnicki D; Weizsäcker K; Hidalgo Tenorio C; Moltó J; Taylor G; Alba-Alejandre I; van Crevel R; Colbers A; Burger D;
Clin Infect Dis; 2021 Jan; 72(1):121-127. PubMed ID: 32103260
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?
Liu XI; Green DJ; van den Anker JN; Rakhmanina NY; Ahmadzia HK; Momper JD; Park K; Burckart GJ; Dallmann A
Front Pediatr; 2021; 9():723006. PubMed ID: 34733804
[No Abstract] [Full Text] [Related]
8. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.
Schalkwijk S; Colbers A; Konopnicki D; Gingelmaier A; Lambert J; van der Ende M; Moltó J; Burger D;
Clin Infect Dis; 2017 Oct; 65(8):1335-1341. PubMed ID: 28595298
[TBL] [Abstract][Full Text] [Related]
9. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy.
Chen J; You X; Wu W; Guo G; Lin R; Ke M; Huang P; Lin C
Eur J Pharm Sci; 2023 Feb; 181():106349. PubMed ID: 36496167
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
Freriksen JJM; Schalkwijk S; Colbers AP; Abduljalil K; Russel FGM; Burger DM; Greupink R
Clin Pharmacol Ther; 2020 Jun; 107(6):1352-1361. PubMed ID: 31868223
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.
Liu XI; Momper JD; Rakhmanina N; van den Anker JN; Green DJ; Burckart GJ; Best BM; Mirochnick M; Capparelli EV; Dallmann A
J Clin Pharmacol; 2020 Feb; 60(2):240-255. PubMed ID: 31489678
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Maternal and Fetoplacental Concentrations of Cefazolin, Cefuroxime, and Amoxicillin during Pregnancy Using Bottom-Up Physiologically Based Pharmacokinetic Models.
Abduljalil K; Ning J; Pansari A; Pan X; Jamei M
Drug Metab Dispos; 2022 Apr; 50(4):386-400. PubMed ID: 35046066
[TBL] [Abstract][Full Text] [Related]
13. Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy.
Pillai VC; Shah M; Rytting E; Nanovskaya TN; Wang X; Clark SM; Ahmed MS; Hankins GDV; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2022 Jan; 88(1):271-281. PubMed ID: 34185331
[TBL] [Abstract][Full Text] [Related]
14. Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model.
Lartey D; Jateng D; Li M; Nguyen C; Crentsil V; Beitz J; George B
Br J Clin Pharmacol; 2023 Jun; ():. PubMed ID: 37312614
[TBL] [Abstract][Full Text] [Related]
15. Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy.
Atoyebi S; Bunglawala F; Cottura N; Grañana-Castillo S; Montanha MC; Olagunju A; Siccardi M; Waitt C
Br J Clin Pharmacol; 2024 Feb; ():. PubMed ID: 38340019
[TBL] [Abstract][Full Text] [Related]
16. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.
Anoshchenko O; Storelli F; Unadkat JD
Drug Metab Dispos; 2021 Oct; 49(10):919-928. PubMed ID: 34426410
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.
Abduljalil K; Pansari A; Ning J; Jamei M
Clin Pharmacokinet; 2022 May; 61(5):725-748. PubMed ID: 35067869
[TBL] [Abstract][Full Text] [Related]
18. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
[TBL] [Abstract][Full Text] [Related]
19. A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.
Scholz EMB; Cao Y; Kashuba ADM
J Antimicrob Chemother; 2021 Oct; 76(11):2890-2893. PubMed ID: 34374767
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.
Hodel EM; Marzolini C; Waitt C; Rakhmanina N
Curr Pharm Des; 2019; 25(5):556-576. PubMed ID: 30894103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
